BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23001792)

  • 1. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
    Benoit YD; Laursen KB; Witherspoon MS; Lipkin SM; Gudas LJ
    J Cell Physiol; 2013 Apr; 228(4):764-72. PubMed ID: 23001792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
    Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
    Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
    Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
    Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
    Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
    Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
    Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
    Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
    Kim SY; Hong M; Heo SH; Park S; Kwon TK; Sung YH; Oh Y; Lee S; Yi GS; Kim I
    Mol Carcinog; 2018 Nov; 57(11):1492-1506. PubMed ID: 29964331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.
    Yan J; Ng SB; Tay JL; Lin B; Koh TL; Tan J; Selvarajan V; Liu SC; Bi C; Wang S; Choo SN; Shimizu N; Huang G; Yu Q; Chng WJ
    Blood; 2013 May; 121(22):4512-20. PubMed ID: 23529930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells.
    Benoit YD; Witherspoon MS; Laursen KB; Guezguez A; Beauséjour M; Beaulieu JF; Lipkin SM; Gudas LJ
    Exp Cell Res; 2013 Jun; 319(10):1463-70. PubMed ID: 23588203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
    Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
    Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic silencing of Bim transcription by Spi-1/PU.1 promotes apoptosis resistance in leukaemia.
    Ridinger-Saison M; Evanno E; Gallais I; Rimmelé P; Selimoglu-Buet D; Sapharikas E; Moreau-Gachelin F; Guillouf C
    Cell Death Differ; 2013 Sep; 20(9):1268-78. PubMed ID: 23852375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
    Li Y; Ren Y; Wang Y; Tan Y; Wang Q; Cai J; Zhou J; Yang C; Zhao K; Yi K; Jin W; Wang L; Liu M; Yang J; Li M; Kang C
    Theranostics; 2019; 9(16):4608-4623. PubMed ID: 31367244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer.
    Li Z; Wang Y; Qiu J; Li Q; Yuan C; Zhang W; Wang D; Ye J; Jiang H; Yang J; Cheng J
    Oncotarget; 2013 Dec; 4(12):2532-49. PubMed ID: 24345883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
    Katona BW; Liu Y; Ma A; Jin J; Hua X
    Cancer Biol Ther; 2014; 15(12):1677-87. PubMed ID: 25535899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
    Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
    Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.
    Girard N; Bazille C; Lhuissier E; Benateau H; Llombart-Bosch A; Boumediene K; Bauge C
    PLoS One; 2014; 9(5):e98176. PubMed ID: 24852755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
    Liu TP; Lo HL; Wei LS; Hsiao HH; Yang PM
    Anticancer Drugs; 2015 Feb; 26(2):139-47. PubMed ID: 25203626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2.
    Dudakovic A; Camilleri ET; Xu F; Riester SM; McGee-Lawrence ME; Bradley EW; Paradise CR; Lewallen EA; Thaler R; Deyle DR; Larson AN; Lewallen DG; Dietz AB; Stein GS; Montecino MA; Westendorf JJ; van Wijnen AJ
    J Biol Chem; 2015 Nov; 290(46):27604-17. PubMed ID: 26424790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
    Chen H; Tu SW; Hsieh JT
    J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.